|
Market Closed -
Nasdaq
04:00:01 2026-11-20 pm EST
|
5-day change | 1st Jan Change | ||
| 27.42 USD | -1.93% |
|
-4.89% | +0.96% |
| Nov. 19 | Celldex ends eczema drug development after mid-stage trial failure | RE |
| Nov. 19 | Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Atopic Dermatitis | CI |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CLDX | Delayed | |
| CLDX | Real-time | ||
| TCE2 | Real-time | ||
| TCE2 | Delayed | ||
| TCE2 | Delayed | ||
| TCE1 | End-of-day quote | ||
| TCE2 | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Neutral |
| Resistance | 28.97 | 34.77 | 41.95 |
| Spread/Res. | -5.35% | -21.14% | -34.64% |
| Spread/Supp. | +4.42% | +21.43% | +19.22% |
| Support | 26.26 | 22.58 | 23 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- CLDX Stock
- Charts Celldex Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















